SASB

Home > SASB > Medicine supply chain integrity > HC-DR-250a.2

Data pertaining to 2024

Overview Retail energy management Controlled substances management Medicine supply chain integrity Activity metrics Patient health outcomes Data security and privacy

Medicine supply chain integrity

GRI HC-DR-250a.2

Number of drug recalls issued, Total units recalled, Percentage for private-label products

We had 42 medication recalls, of which only one unit (2.4%) involved an Exclusive Brand product, and this was a voluntary recall. We do not track the number of units recalled.